The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma: ECOG-ACRIN EA2187.
 
Anita Turk
Consulting or Advisory Role - Jazz Pharmaceuticals; KLM Solutions
Research Funding - Lilly (Inst); Merck (Inst)
 
Noah Graham
No Relationships to Disclose
 
Dustin Deming
Consulting or Advisory Role - DoMoreDx; Foundation Medicine; Illumina; Inocras; Pfizer; Regeneron; Seagen; Taiho Oncology
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Ipsen; Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Devalingam Mahalingam
Consulting or Advisory Role - Actuate Therapeutics; Amgen; Qurient
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Amgen; Merck KGaA; Oncolytics
 
Anup Kasi
Consulting or Advisory Role - Cardinal Health; Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Boundless Bio (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novita Pharmaceuticals (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Suneel Kamath
Consulting or Advisory Role - BeiGene; Exelixis; Jazz Pharmaceuticals
Speakers' Bureau - AstraZeneca; Merck; Pfizer; Takeda
 
Kathryn Hourdequin
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I); United Health Group (I)
Research Funding - Inspirna (Inst)
Patents, Royalties, Other Intellectual Property - Receive royalties through the University of Minnesota for MNRead low vision eye chart (Inst)
 
Peter O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)